{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-013461","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.711476+00:00","generated_at":"2026-06-25T21:45:41.144271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bioventus Q1 net loss $14.8M vs prior-year income; reaffirms FY22 guidance","bullets":["Net sales $117.3M (+43.4% YoY as reported, +8.6% organic); Pain Treatments +25.3%, Restorative Therapies +57.5%, Surgical Solutions +67.6%.","Net loss of ($14.8M) compared to net income of $24.5M in Q1 2021; Adjusted EBITDA $7.1M vs $11.1M.","Reaffirms FY2022 guidance: net sales $545M-$565M, Adjusted EBITDA $94M-$107M.","Cash $27.4M; debt $368.3M as of April 2, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-013461","json":"https://secwatch.observer/filing/0001628280-22-013461.json","markdown":"https://secwatch.observer/filing/0001628280-22-013461.md","text":"https://secwatch.observer/filing/0001628280-22-013461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022013461/0001628280-22-013461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022013461/bvs-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:45:41.144271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}